Which level of immunosuppression is harmful for occult hepatitis B virus infection?: 'A million dollar' answer

Liver International

Volumn 29, Issue 7, 2009, Pages 1127-1128

  Georgiadou, Sarah P ^a   Dalekos, George N ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; VIRUS DNA;

AUTOIMMUNE HEPATITIS; DRUG DOSE REDUCTION; DRUG SAFETY; HEPATITIS B; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER CIRRHOSIS; MONOTHERAPY; OCCULT HEPATITIS B; PATIENT MONITORING; VIRUS REACTIVATION;

EID: 67650445799     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02063.x     Document Type: Letter

References (8)

1. Ozaslan E. Which level of immunosuppression is harmful for occult hepatitis B virus infection? Liver Int (Letter) 2009.
2. Georgiadou SP, Zachou K, Liaskos C, et al. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 2009; 29: 434-42.
3. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147-53.
4. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
5. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769-74.
6. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74: 254-8.
7. Stefos A, Gatselis N, Zachou K, et al. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. Eur J Intern Med 2009; 20: 35-43.
8. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.